STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs IGF-methotrexate (Primary)
- Indications Haematological malignancies; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Solid tumours; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Acronyms STM-02
- Sponsors IGF Oncology
- 27 Apr 2017 Status changed from recruiting to completed.
- 01 Jun 2014 The study design presented at : 50th Annual Meeting of the American Society of Clinical Oncology.
- 03 Feb 2014 New trial record